ACT-389949
ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2) /Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders[1][2].
Product Specifications
CAS Number
1258417-54-7
UNSPSC
12352005
Hazard Statement
H302
Target
Formyl Peptide Receptor (FPR)
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/act-389949.html
Purity
99.96
Solubility
DMSO : 10 mg/mL (ultrasonic; adjust pH to 1 with HCl)
Smiles
O=C(C1=C(C2=CC=CC(C)=C2)OC(C)=N1)NC3=NN(CC4=NC(C(F)(F)C)=CO4)N=C3
Molecular Formula
C20H18F2N6O3
Molecular Weight
428.39
Precautions
H302
References & Citations
[1]Stalder AK, et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83 (3) :476-486.|[2]Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA610141 100 µg
Kappa Light Chain Recombinant Mouse monoclonal Antibody
Sign In for Pricing
View Details 